DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews
<b>Background/Objectives</b>: Fluoropyrimidines are widely used chemotherapeutic agents in various solid tumors. Germline variants in the DPYD gene, which encodes the enzyme dihydropyrimidine dehydrogenase (DPD), are known to impair drug metabolism and increase the risk of severe toxicit...
Saved in:
| Main Authors: | Sara Otero-Torres, Rosa Rodríguez-Mauriz, Eduard Fort-Casamartina, Ana Clopés-Estela, Francesc Soler-Rotllant, Sandra Fontanals-Martínez, Olalla Montero-Pérez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/5/727 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01) -
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
by: Almudena Gil-Rodríguez, et al.
Published: (2025-03-01) -
Implementation of DPYD testing in Bulgarian patients with cancer
by: Nelly Miteva-Marcheva, et al.
Published: (2024-12-01) -
Pharmacogenomic tests in Oncology - finding the right dose
by: Jeziel Basso, et al.
Published: (2021-10-01) -
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
by: Guilherme Suarez-Kurtz
Published: (2021-10-01)